phospholipid ether-paclitaxel conjugate (CLR 1603-PTX)
/ Cellectar
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 12, 2021
LegoChem, Cellectar to develop PDC-based anticancer therapy
(Korea Biomedical Review)
- “LegoChem Biosciences said that it has signed a collaboration and option license agreement with Cellectar Biosciences, a U.S.-based biopharmaceutical company, in developing a PDC (phospholipid drug conjugates)-based anticancer treatment…Under the accord, the two companies will discover PDC candidates using Cellectar's PLE (Phospholipid Ether) source technology and LegoChem's ADC (antibody-drug conjugate) linker-toxin platform technology.”
Licensing / partnership • Oncology
1 to 1
Of
1
Go to page
1